WRAL Tech Wire

Emory Picks Agencourt for Help in Gene-Disease Link Study

Triangle Pharmaceuticals Settles Patent Dispute for AIDS Drug

AGL Networks To Provide Fiber for Emory

Emory To Be Part of $20M Parkinson's Study

New Triangle Pharma CEO 'Picks up the Baton for the Next Relay'

Daniel Welch says 'raw materials' of Triangle lured him to replace the late Dr. David Barry. He's excited about company's prospects as well as deal to reacquire rights to anti-AIDs drug Coviracil.

USLEC Reports Strong Customer Growth

New Biotech Fund Targets University Spin-offs in Southeast, Mid-Atlantic

D.C.-based University Biomedical Fund already has made its first investment in a UVa drug development concept. Medical faculty from UNC, Duke and Emory are on the $50M fund's advisory board.

Elan To Triple Georgia Drug Plant's Size, Add 100 Workers

The Irish pharmaceutical firm now makes 2 will drugs at the plant and will make 2 more. <b>Other news:</b> Nobex working with Pharmacia, Hamner honored.

Learning the Lessons of Enron: Execs Reminded About Oversight -- and Something Called Honesty

Panel reminds lawyers, auditors and corporate officers of their responsibilities to follow the rules. 'This is not a systemic problem of control systems in the market but a systemic perception - left over from the 'dot com' era - that no rules need a

Execs Gather To Discuss Implications of Enron Debacle and Erosion of Trust

Southeast tech leader John Yates: 'Technology leaders need to understand the implications for their strategic alliances, their boards and their relationships with venture capitalists and accountants.'

Peach of a Deal: Georgia Outdistances North Carolina in Venture Investing

State's push and corporate support have made Atlanta a hub for VC and start-ups, while North Carolina was 'resting too much on past laurels,' one observer says. 'They put a target on our backs,' adds another. But some say comparing states is 'bunk'.

Inhibitex Closes on $41.4 Million; Good News for United Therapeutics; Pappas Adds to Board

Roundup: Inhibitex, developer of drugs to treat bacterial and fungal infections, could get $45.4 million; United gets FDA 'approvable' letter; A.M. Pappas expands West Coast presence.